Latest News From "The Pink Sheet" DAILY

Teva's Growth Strategy In Europe: Bullish on Germany (Part 1 of 2)

The head of Teva's EU business explains why the troubled German market remains a key opportunity for his firm. read_more_>

 

FDA Approves Ampyra Despite Slight Responder Rate and Seizure Risk

FDA approved Ampyra extended release tablets with the novel indication of improvement in walking ability in adults with multiple sclerosis. read_more_>

 

In A First Of Sorts, GSK To Map Breast Cancer Sub-types In India For Research Leads

The program will be steered through GlaxoSmithKline's newly formed Oncology Ethnic Research Initiative, which supports projects to improve understanding of the epidemiology and genetics of breast cancer in ethnically diverse non-Caucasian populations. read_more_>

 

Renewing Old Ties, Celtic Therapeutics Leads $10 Billion Series B For Kolltan

Financing includes $1.5 million development option that converts to another Series B if there’s no agreement on a co-development program. read_more_>

 

Long-Term Thinking In Chronic Pain: An Interview With King CEO Brian Markison (Part 1)

King Pharmaceuticals sees a sustainable model in innovative drug delivery for chronic pain therapy. But is the company big enough and focused enough to succeed? read_more_>